Head and Neck Squamous Cell Carcinoma
Conditions
Brief summary
The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head & Neck Squamous Cell Carcinoma Secondary purposes are: * Study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (CTCs); * Study of relationship between qualitative (yes/no) and quantitative (number) presence of CTCs and clinical stage as well as DFS * Study of relationship between anti-tumor immune response and clinical stage as well as DFS.
Interventions
OTHERBlood sample
Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with Head & Neck Squamous Cell Carcinoma after extension assessment, regardless of clinical stage (TNM UICC stage I-IV), before any medical or surgical treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy or targeted therapy) * Consent to participate to the study, non-opposition * Affiliation to social security
Exclusion criteria
* History of neoplasia, synchronous cancer, auto-immune disease, organ transplantation, chemotherapy * HIV infection * Corticotherapy during 15 days before blood sampling
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence or absence of spontaneous responses against tumor-associated antigens (TAA) according to tumor stage | day 0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Functional signature of T cell responses (polyfunctionality index of lymphocytes) according to tumor stage | day 0 | Effector functions and phenotypes of T cells |
| Number of CTCs according to tumor stage | day 0 | — |
| Polyfunctionality index of lymphocytes according to number of CTCs | day 0 | — |
| Disease free survival (survival without local or distant recurrence) according to Presence pr absence of CTCs at diagnosis | 2 years after diagnosis | — |
| Disease free survival (survival without local or distant recurrence) according to Presence or absence of spontaneous responses against TAA | 2 years after diagnosis | — |
Countries
France
Contacts
Primary ContactPatrice GALLET
Backup ContactMarcelo DE CARVALHO
Outcome results
None listed